Race to Finding COVID-19 Cure: Could Traditional Herbal Medicine Hold the “Silver Bullet”? An Appraisal of Research Evidence

  • Adejuwon Adeneye Department of Pharmacology, Therapeutics and Toxicology, Faculty of Basic Clinical Sciences, Lagos State University College of Medicine, 1-5 Oba Akinjobi Way, G.R.A., Ikeja, Lagos State, Nigeria
Keywords: 2019-nCoV infection, Traditional Herbal Medicine, Basic studies, Clinical trials, Clinical outcomes

Abstract

Background: The global index case of the ongoing novel 2019-nCoV infection was recorded in China in December 2019 and the infection is currently considered global public health and security threat due to its high infectivity, associated high mortality and morbidity, fast replication and mutations and lack of clinically approved drugs and vaccines for its treatment. These have since spurred global race for the discovery and development of effective and safe chemotherapeutic and chemoprophylactic agent(s) for its treatment. In order to harness the potentials and bring to the attention of stakeholders in the healthcare industry anti-COVID-19 potentials inherent in plant-derived bioactive compounds, the present study is designed to rapidly review published basic and clinical studies on traditional medicinal plants with proven anti-COVID-19 natural compounds is undertaken.

Methods: Eight online database search engines using some COVID-19 keywords were used to search for literature from between 1 December 2019 and 15 May 2020. Of 218 hits retrieved, only 19 peer-reviewed and published works fulfilled the set criteria and reviewed.

Results: Using network pharmacology screening and molecular docking technology, natural bioactive compounds, quercetin, kaempferol, and luteoline were the most prevalent and effective bioactive compounds that directly inhibited SARS-CoV-2 protease and down-regulated inflammation. Also the few clinical studies reviewed showed that COVID-19 positive patients managed with traditional herbal remedies either alone or in combination with conventional antiviral regimen and palliative treatment experienced significant clinical improvements.

Conclusions: Overall, these studies provided new evidence to support the possible therapeutic role traditional herbal medicine could offer in the clinical management and prevention of COVID-19. However, more robust and multicenter human trials are still required to verify the efficacy and safety of these remedies.

References

Guo, Y. R.; Cao, Q, D.; Hong, Z. S.; Tan, Y. Y.; Chen, S. D.; Jin, H. J.; Tan, K. S.; Wang, D. Y.; Yan, Y.; “The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status”, Mil. Med. Res. 7(1), 11, 2020.

https://doi.org/10.1186/s40779-020-00240-0.

Lu, R.; Zhao, X.; Li, J.; Niu, P.; Yang, B.; Wu, H.; Wang, W.; Song, H.; Huang, B.; Zhu, N.; Bi, Y.; Ma, X.; Zhan, F.; Wang, L.; Hu, T.; Zhou, H.; Hu, Z.; Zhou, W.; Zhao, L.; Chen, J; Meng, Y., Wang, J.; Lin, Y.; Yuan, J.; Xie, Z.; Ma, J.; Liu, W.J.; Wang, D.; Xu, W., Holmes, E.C.; Gao, G.F.; Wu, G.; Chen, W.; Shi, W.; Tan, W.; “Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding”, Lancet 395, 565–574, 2020.

Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R.; Niu, P.; Zhan, F.; Ma, X.; Wang, D.; Xu, W.; Wu, G.; Gao, G.F.; Tan, W.; China Novel Coronavirus Investigating and Research Team; “A novel coronavirus from patients with pneumonia in China, 2019”, N. Engl. J. Med. 382, 727–733, 2020.

Huang, C.; Wang, Y.; Li, X-W.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; Cheng, Z.; Yu, T.; Xia, J.; Wei, Y.; Wu, W.; Xie, X.; Yin, W.; Li, H.; Liu, M.; Xiao, Y.; Gao, H.; Guo, L.; Xie, J.; Wang, G.; Jiang, R.; Gao, Z.; Jin, Q., Wang, J.; Cao, B.; “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”, Lancet 395, 497–506, 2020.

Hopkins, C.; Surda, P.; Whitehead, E.; Kumar, B.N.; “Early recovery following new onset anosmia during the COVID-19 pandemic – an observational cohort study”, J. of Otolaryngol. – Head and Neck Surg. 49, 26. https://doi.org/10.1186/s40463-020-00423-8.

Bénézit, F.; Le Turnier, P.; Declerck, C.; Paillé, C.; Revest, M.; Dubée, V.; Tattevin, P.; for the RAN COVID Study Group; “Utility of hyposmia and hypogeusia for the diagnosis of COVID-19”, Lancet Infect. Dis. S1437, 30297–30298, 2020.

Guan, W.; Ni, Z.; Hu, Y.; Liang, W.; Ou, C.; He, J.; Liu, L.; Shan, H.; Lei, C.; Hui, D.S.C.; Du, B.; Li, L.; Zeng, G.; Yuen, K-Y.; Chen, R.; Tang, C.; Wang, T.; Chen, P.; Xiang, J.; Li, S., Wang, J-L.; Liang, Z.; Peng, Y.; Wei, L.; Liu, Y.; Hu, Y-H.; Peng, P.; Wang, J-M.; Liu, J.; Chen, Z.; Li, G.; Zheng, Z.; Qiu, S.; Luo, J.; Ye, C.; Zhu, V.; Zhong, N.; for the China Medical Treatment Expert Group for Covid-19; “Clinical characteristics of coronavirus disease 2019 in China”, N. Engl. J. Med., published online Feb 28, 2020. http://doi:10.1056/NEJMoa2002032.

Wu, P.; Duan, F.; Luo, C.; Liu, Q.; Qu, X.; Liang, L.; Wu, K.; “Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19) in Hubei Province, China”, JAMA Ophthalmol. e201291, 2020.

https://doi.org:10.1001/jamaophthalmol.2020.1291.

Kim, J.; Thomsen, T.; Sell, N.; Goldsmith, A.J.; “Abdominal and testicular pain: An atypical presentation of COVID-19”, Am. J. Emerg. Med. S0735-6757-675735-6757(20)30194-7. https://doi.org/10.1016/j.ajem.2020.03.052.

Toscano, G.; Palmerini, F.; Ravaglia, S.; Ruiz, L.; Invernizzi, P.; Cuzzoni, M.G.; Baldanti, F.; Daturi, R.; Postorino, P.; Cavallini, A.; Micieli, G.; “Guillain-Barré syndrome associated with SARS-CoV-2”, N. Engl. J. Med. Published online April 17, 2020. http://doi:10.1056/NEJMc2009191.

Zhao, H.; Shen, D.; Zhou, H.; Liu, J.; Chen, S.; “Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence?”, Lancet Neurol. 19(5), 383–384, 2020.

Edirappuli, S. D.; Venkatesh, A.; “Atypical symptoms in COVID-19: the many guises of a common culprit. Rapid response to: Covid-19: four fifths of cases are asymptomatic, China figures indicate” Br. Med. J. 369, m1375, 2020.

Zaim, S.; Jun Heng Chong, J. H.; Sankaranarayanan, V.; Harky, A.; “COVID-19 and multi-organ response”. Curr. Prob. Cardiology 2020. https://doi.org/10.1016/j.cpcardiol.2020.100618.

World Health Organization; “WHO Coronavirus Disease (COVID-19) Dashboard”.

https://www.covid19.who.int/

Food and Drug Administration; “Coronavirus (COVID-19) Update: FDA issues emergency use authorization for potential COVID-19 treatment”, FDA News Release 01 May 2020.

https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment.

World Health Organization Africa; “WHO supports scientifically-proven traditional medicine” https://www.afro.who.int/news/who-supports-scientifically-proven-traditional-medicine. 04 May 2020.

Liu, J.; Manheimer, E.; Shi, Y.; Gluud, C.; “Chinese herbal medicine for severe acute respiratory syndrome: a systematic review and meta-analysis”, J. Altern. Complement. Med. 10, 1041–1051, 2004.

Chen, Z.; Nakamura, T.; “Statistical evidence for the usefulness of Chinese medicine in the treatment of SARS”, Phytother. Res. 18, 592–594, 2004.

Liu, X.; Zhang, M.; He, L.; Li, Y.; “Chinese herbs combined with Western medicine for severe acute respiratory syndrome (SARS)”, Cochrane Database Syst. Rev. 10, CD004882, 2012.

http://doi:10.1002/14651858.CD004882.pub3.

Park, J. Y.; Yuk, H. J.; Ryu, H. W.; Lim, S. H.; Kim, K. S.; Park, K. H.; Ryu, Y. B.; Lee, W. S.; “Evaluation of polyphenols from Broussonetia papyrifera as coronavirus protease inhibitors”, J. Enzyme Inhib. Med Chem. 32(1), 504–515, 2017.

Kim, J. Y.; Kim, Y. I.; Park, S. J.; Kim, I. K.; Choi, Y. K.; Kim, S. H.; “Safe, high-throughput screening of natural compounds of MERS-CoV entry inhibitors using a pseudovirus expressing MERS-CoV spike protein”, Int. J. Antimicrob. Agents 52(5), 730–732, 2018.

Aanouz, I.; Belhassan, A.; El-Khatabi, K.; Lakhlifi, T.; El-ldrissi, M.; Bouachrine, M.; “Moroccan Medicinal plants as inhibitors against SARS-CoV-2 main protease: Computational investigations” J. Biomol. Struct. Dyn., 1–9, 2020.

Soleymani, S.; Zabihollahi, R.; Shahbazi, S.; Bolhassani, A.; “Antiviral effects of saffron and its major ingredients”, Curr. Drug Deliv. 15(5), 698-704, 2018.

Wong, R. W.; Lingwood, C. A.; Ostrowski, M. A.; Cabral, T.; Cochrane, A.; “Cardiac glycoside/aglycones inhibit HIV-1 gene expression by a mechanism requiring MEK1/2-ERK1/2 signaling”, Sci. Rep. 8(1), 850, 2018.

https://doi.org/10.1038/s41598-018-19298-x.

Sanna, G.; Madeddu, S.; Serra, A.; Collu, D.; Efferth, T.; Hakkim, F.L.; Rashan, L.; “Anti-poliovirus activity of Nerium oleander aqueous extract”, Nat. Prod. Res., 1–4, 2019. http://doi.org/10.1080/14786419.2019.1582046.

Boff, L.; Munkert, J.; Ottoni, F. M.; Zanchett-Schneider, N. F.; Ramos, G. S.; Kreis, W.; Fernandes de Andrade, S.; Dias de Souza Filho, J.; Braga, F.C.; Alves, R.J.; Maia de Pádua, R.; Oliveira Simões, C.M.; “Potential anti-herpes and cytotoxic action of novel semisynthetic digitoxigenin-derivatives”, Eur. J. Med. Chem. 167, 546–561, 2019.

Astani, A.; Reichling, J.; Schnitzler, P.; “Screening for antiviral activities of isolated compounds from essential oils”, Evid. Based Complement. Altern. Med., 253643, 2011.

https://doi.org/10.1093/ecam/nep187.

Alejo-Armijo, A.; Altarejos, J.; Salido, S.; “Phytochemicals and biological activities of Laurel tree (Laurus nobilis)”, Nat. Prod. Commun. 12(5), 743–757, 2017.

Yu, S.; Wang, J.; Shen, H.; “Network pharmacology-based analysis of the role of traditional Chinese herbal medicines in the treatment of COVID-19”, Annals of Palliative Medicine 9(2), 437–446, 2020.

Zhang, D-H.; Zhang, X.; Peng, B.; Deng, S-Q.; Wang, Y-F.; Yang, L.; Zhang, K-Z.; Lin, C-Q.; Wu, K-L.; “Molecular basis for treating COVID-19 with official Chinese herbal formula LCTE”, Research Square 03 April 2020.

https://doi.org/10.21203/rs.3.rs-20828/v1.

Zhang, D-H.; Wu, K-L.; Zhang, X.; Deng, S-Q.; Peng, B.; In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus. J. Integr. Med. 8(2), 152–158, 2020.

Zhu, J.; Deng, Y-Q.; Wang, X.; Li, X-F.; Zhang, N-N.; Liu, Z.; Zhang, B.; Qin, C-F.; Xie, Z.; “An artificial intelligence system reveals liquiritin inhibits SARSCoV-2 by mimicking type I interferon”, bioRxiv 2020.

https://doi.org/10.1101/2020.05.02.074021.

Zhao, J,; Tian, S-S.; Yang, J.; Liu, J-F.; Zhang, W-D. “Investigating the mechanism of Qing-Fei-Pai-Du-Tang for the treatment of novel coronavirus pneumonia by network pharmacology”, Chinese Trad. Herb. Drugs 51(2), 2020.

http://jtp.cnki.net/bilingual/detail/html/ZCYO20200216002.

Kim, H-Y.; Eo, E-Y.; Park, H.; Kim, Y-C.; Park, S.; Shin, H-J.; Kim, K.; “Medicinal herbal extracts of Sophorae radix, Acanthopanacis cortex, Sanguisorbae radix and Torilis fructus inhibit coronavirus replication in vitro. Antivir. Ther. 15, 697–709, 2010.

Li, Z.; Yu, K-X.; “Exploration on anti-coronavirus mechanism of Radix sophorae flavescentis via multiple pathways”, Chinese Trad Herb. Drugs 51(2), 2020.

http://jtp.cnki.net/bilingual/detail/html/ZCYO20200218002.

Zong, Y.; Ding, M-L.; Jia, K-K.; Ma, S-T., Ju, W-Z.; “Exploring the active compounds of Da-Yuan-Yin in treatment of novel coronavirus (2019-nCoV) pneumonia based on network pharmacology and molecular docking method”, Chinese Trad. Herb. Drugs 51(4), 2020.

http://jtp.cnki.net/bilingual/detail/html/ZCYO20200208000.

Ling, X-Y.; Tao, J-L.; Sun, X.; Yuan, B.; “Exploring material basis and mechanism of Lianhua Qingwen formula against coronavirus based on network pharmacology”, Chin. Traditional and Herbal Drugs 51(3), 2020.

http://jtp.cnki.net/bilingual/detail/html/ZCYO20200320001.

Gong, P-Y.; Guo, Y-J.; Li, X-P.; Wang, N.; Gu, J.; “Exploring active compounds of Jinhua Qinggan granules for prevention of novel coronavirus pneumonia (COVID-19) based on network pharmacology and molecular docking”, Chin. Trad. Herb. Drugs 51(3), 2020.

http://jtp.cnki.net/bilingual/detail/html/ZCYO20200325000.

Deng, Y-J.; Liu, B-W.; He, Z-X.; Liu, T.; Zheng, R-L.; Yang, A-D.; Huang, A.; Li, Y-T.; Xu, Y-L.; “Study on active compounds from Huoxiang Zhengqi oral liquid for prevention of coronavirus disease 2019 (COVID-19) based on network pharmacology and molecular docking”, Chin. Trad. Herb. Drugs 54(5), 1113–1122, 2020.

Yao, Y-X.; He, Z-X.; Liu, X-F.; He, Y-Z.; Lei, Y.; Zhang, S-T.; Zhao L-L.; Liu, T.; Potential material basis of Kangbingdu granules for treatment of coronavirus disease (COVID-19) based on network pharmacology and molecular docking technology. Chin. Trad. Herb. Drugs 51(6), 1386–1396, 2020.

Enmozhi, S.K.; Raja, K.; Sebastine, I.; Joseph, J.; “Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in silico approach”, J. Biomol Struct Dyn 2020.

http://doi:10.1080/07391102.2020.1760136.

Luo, E.; Zhang, D.; Luo, H.; Liu, B.; Zhao, K.; Zhao, Y.; Bian, Y.; Wang, Y.; “Treatment efficacy analysis of traditional Chinese medicine for novel coronavirus pneumonia (COVID-19): an empirical study from Wuhan, Hubei Province, China”, Chin. Med. 15, 34, 2020. https://doi.org/10.1186/s13020-020-00317-x.

National Health Commission of the People’s Republic of China; “TCM use reduces COVID-19 death risk: expert”, 2020.

http://en.nhc.gov.cn/2020-04/18/c_79343.htm.

Ren, J-L.; Zhang, A-H.; Wang, X-J.; “Traditional Chinese medicine for COVID-19 treatment”, Pharmacol. Res. 155, 104743, 2020.

Wang, Z.; Chen, X.; Lu, Y.; Chen, F.; Zhang, W.; Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment”, Biosci. Trends 14(1), 64–68, 2020.

Wan, S.; Xiang, Y.; Fang, W.; Zheng, Y.; Li, B.; Hu, Y.; Lang, C.; Huang, D.; Sun, Q.; Xiong, Y.; Huang, X.; Lv, J.; Shen, L.; Yang, H.; Huang, G.; Yang, R.; “Clinical features and treatment of COVID-19 patients in northeast Chongqing”, J. Med. Virol. [published ahead of print 2020 March 21]. http://doi:10.1002/jmv.25783.

Parikh, N.; Parikh, D.; “Role of homoeopathy in COVID-19 Management- A clinical experience”, World J. Pharm. Res. 9(5), 2459, 2020.

Lythgoe, M.P.; Middleton, P.; “Ongoing clinical trials for the management of the COVID-19 pandemic”, Trends Pharmacol. Sci. 41(6), 363–382, 2020.

Caly, L.; Druce, J. D.; Catton, M. G.; Jans, D. A.; Wagstaff, K. M.; “The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro”, Antivir. Res. 178, 104787, 2020.

Ko, W. C.; Rolain, J. M.; Lee, N. Y.; Chen, P. L.; Huang, C. T.; Lee, P. I.; Hsueh, P. R.; “Arguments in favour of remdesivir for treating SARS-CoV-2 infections”, Int. J. Antimicrob. Agents 55(4), 105933, 2020.

Wu, R.; Wang, L.; Kuo, H. D.; Shannar, A.; Peter, R.; Chou, P. J.; Li, S.; Hudlikar, R.; Liu, X.; Liu, Z.; Poiani, G. J.; Amorosa, L.; Brunetti, L.; Kong, A-N.; “An update on current therapeutic drugs treating COVID-19”, Curr. Pharmacol. Rep. 2020, 1–15.

https://doi.org/10.1007/s40495-020-00216-7.

Şimşek, Y. S.; Ünal, S.; “Antiviral treatment of COVID-19”, Turk. Med. J. Sci. 50(SI-1), 611–619, 2020.

Hung, I. F.; Lung, K-C.; Tso, E. Y-K.; Liu, R.; Chung, T. W-H.; Chu, M-Y.; Ng, Y-Y.; Lo, J.; Chan, J.; Tam, A. R.; Shum, H-P.; Chan, V.; Wu, A. K-L., Sin, K-M., Leung, W-S., Law, W-L.; Lung, D. C.; Sin, S.; Yeung, P.; Yip, C. C-Y.; Zhang, R. Z.; Fung, A. Y-F.; Yan, E. Y-W., Leung, K-H., Ip, J. D.; Chu, A. W-H.; Chan, W-M.; Ng, A. C-K.; Lee, R.; Fung, K.; Yeung, A.; Wu, T-C.; Chan, J. W-M.; Yan, W-W.; Chan, W-M.; Chan, J. F-W.; Lie, A. K-W.; Tsang, O. T-Y.; Cheng, V. C-C.; Que, T-L.; Lau, C-S.; Chan, K-H.; To, K. K-W., Yuen, K-Y.; “Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomized, Phase 2 trial”, Lancet, S0140-6736(20), 31042-4, 2020.

https://doi.org/10.1016/S0140-6736(20)31042-4.

Ford, N.; Vitoria, M.; Rangaraj, A.; Norris, S. L.; Calmy, A.; Doherty, M.; “Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment”, J. Int. AIDS Soc. 23, e25489, 2020.

Tillu, G.; Chaturvedi, S.; Chopra, A.; Patwardhan, B.; “Public health approach of Ayurveda and Yoga for COVID-19 prophylaxis”, J. Altern. Complement. Med 26(5), 360–364, 2020.

Zhang, R.; Zhu, X.; Bai, H.; Ning, K.; “Network pharmacology databases for traditional Chinese medicine: review and assessment”, Front. Pharmacol. 10, 123, 2019.

http://doi:10.3389/fphar.2019.00123.

Jin, Z.; Du, X.; Xu, Y.; Deng, Y.; Liu, M.; Zhao, Y.; Zhang; B.; Li, X-F.; Zhang, L.; Duan, Y.; Yu, J.; Wang, L.; Yang, K.; Liu, F.; You, T.; Liu, X.; Yang, X.; Bai, F.; Liu, H.; Liu, X.; Guddat, L.W.; Xiao, G.; Qin, C-F.; Shi, Z.; Jiang, H.; Rao, Z.; Yang, H.; “Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors”, Nature 2020.

https://doi.org/10.1038/s41586-020-2223-y.

Kim, Y.; Narayanan, S,; Chang, K.O.; “Inhibition of influenza virus replication by plant-derived isoquercetin”, Antivir. Res. 88, 227-235, 2010.

Qiu, X.; Alimonti, J.; Melito, L.; Fernando, L.; Stroher, U.; Jones, S.; “Characterization of Zaire ebola virus glycoprotein-specific monoclonal antibodies”, Clin. Immunol. 141, 218–227, 2011.

Jo, S.; Kim, H.; Kim, S.; Shin, D. H.; Kim, M-S.; “Characteristics of flavonoids as potent MERS-Cov 3C-like protease inhibitors”, Chem. Bio. Drug Des. 94, 2023–2030, 2019.

Jo, S.; Kim, S.; Shin, D. H.; Kim, M-S.; “Inhibition of SARS-CoV 3CL protease by flavonoids”, J. Enzyme Inhib. Med. Chem. 35(1), 145–151, 2020.

Hoever, G.; Baltina, L.; Michaelis, M.; Kondratenko, R.; Baltina, L.; Tolstikov, G. A.; Doerr, H. W.; Cinatl, J. Jr.; “Antiviral activity of glycyrrhizic acid derivatives against SARS-coronavirus”, J. Med. Chem. 48(4), 1256–1259, 2005.

Ishfaq, M.; Chen, C.; Bao, J.; Zhang, W.; Wu, Z.; Wang, J.; Liu, Y.; Tian, E.; Hamid, S.; Li, R.; Ding, L.; Li, J.; “Baicalin ameliorates oxidative stress and apoptosis by restoring mitochondrial dynamics in the spleen of chickens via the opposite modulation of NF-kappaB and Nrf2/HO-1 signaling pathway during Mycoplasma gallisepticum infection”, Poult. Sci. 98(12), 6296–6310, 2019.

Baglivo, M.; Baronio, M.; Natalini, G.; Beccari, T.; Chiurazzi, P.; Fulcheri, E.; Petralia, P.P.; Michelini, S.; Fiorentini, G.; Miggiano, G.A.; Morresi, A.; Tonini, G.; Bertelli, M.; “Natural small molecules as inhibitors of coronavirus lipid-dependent attachment to host cells: a possible strategy for reducing SARS-COV-2 infectivity?”, Acta Biomed. 91(1), 161–164, 2020.

Rao, A. S.; “Root flavonoids”, Bot. Rev. 56(1), 1–84, 1990.

Huang, L.; Li, W.; Feng, Y.; Fang, X.; Li, J.; Gao, Z.; Li, H.; “Simultaneous recovery of glycyrrhizic acid and liquiritin from Chinese licorice root (Glycyrrhiza uralensis Fisch) by aqueous two-phase system and evaluation biological activities of extracts”, Sep. Sci. Technol. 53(9), 1342–1350, 2018.

Kuang, Y.; Li, B.; Fan, J.; Qiao, X.; Ye, M.; “Antitussive and expectorant activities of licorice and its major compounds”, Bioorgan. Med. Chem. 26(1), 278–284, 2018.

Zhou, P.; Hua, F.; Wang, X.; Huang, J-L.; “Therapeutic potential of IKK-β inhibitors from natural phenolics for inflammation in cardiovascular diseases”, Inflammopharmacology 28, 19–37, 2020.

Wei, W.; Wan, H.; Peng, X.; Zhou, H.; Lu, Y.; He, Y.; “Antiviral effects of Ma Huang Tang against H1N1 influenza virus infection in vitro and in an ICR pneumonia mouse model”, Biomed. Pharmacother. 102, 1161–1175, 2018.

Perrotta, F.; Matera, M. G.; Cazzola, M.; Bianco, A.; “Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter?”, Respir. Med. 168, 105996, 2020.

Published
2020-06-01
How to Cite
Adeneye, A. (2020). Race to Finding COVID-19 Cure: Could Traditional Herbal Medicine Hold the “Silver Bullet”? An Appraisal of Research Evidence. Al-Nahrain Journal of Science, 3(1), 12-25. Retrieved from https://anjs.edu.iq/index.php/anjs/article/view/2266